0000000000515934

AUTHOR

R. Myers

showing 2 related works from this author

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis

2021

ObjectiveLiver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies.DesignIndividual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were c…

Liver CirrhosisMaleCirrhosisLIVER STIFFNESS MEASUREMENTBiopsy[SDV]Life Sciences [q-bio]biostatisticsGastroenterologyDISEASEbiostatistics; clinical decision making; fatty liver; hepatic fibrosis0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosishepatic fibrosis2. Zero hunger0303 health sciencesmedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISTRANSIENT ELASTOGRAPHYFatty liverGastroenterologyCHRONIC HEPATITISMiddle Aged3. Good healthSettore AGR/03 - Arboricoltura Generale E Coltivazioni ArboreeLiverLiver biopsyBIOPSYElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyMedian bodymedicine.medical_specialtyCONTROLLED ATTENUATION PARAMETER610 Medicine & healthclinical decision making03 medical and health sciencesInternal medicineSCOREmedicineHumansbiostatistics clinical decision making fatty liver hepatic fibrosisfatty liver030304 developmental biologyReceiver operating characteristicbusiness.industrymedicine.diseaseFibrosisDiabetes Mellitus Type 2XL PROBEbusinessHepatic fibrosisTransient elastographyBiomarkersPROSPECTIVE DERIVATIONGut : the journal of the British Society for Gastroenterology
researchProduct

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

2022

Background & Aims Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods We profiled 2,083 serum miRNAs in a discovery cohort (183 cases with NAFLD representing the complete NAFLD spectrum and 10 population controls). miRNA libraries generated by HTG EdgeSeq were sequenced by Illumina NextSeq. Selected serum miRNAs were profiled in 372 additional cases with NAFLD and 15 population controls by quantitative reverse transcriptase PCR. Results Levels of 275 miRNAs differed between cases and population controls. Fewer differences were seen wi…

SCORING SYSTEMCPM counts per millionAUROC area under the receiver operating characteristicRC799-869AST aspartate aminotransferaseMicroRNA; Non-alcoholic fatty liver disease; Biomarker; SequencingTGF-β transforming growth factor-betaGastroenterologySTEATOHEPATITISLiver disease0302 clinical medicineFibrosismiRNA microRNAlogFC log2 fold changeFIBROSISImmunology and AllergySequencing0303 health scienceseducation.field_of_studyNAS NAFLD activity scoremedicine.diagnostic_testFatty liverGastroenterologyGTEx Genotype-Tissue ExpressionMicroRNADiseases of the digestive system. Gastroenterology3. Good healthReal-time polymerase chain reactionBiomarker MicroRNA Non-alcoholic fatty liver disease SequencingLiver biopsyACIDBiomarker (medicine)030211 gastroenterology & hepatologyLife Sciences & BiomedicineResearch ArticleEXPRESSIONmedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseNASH non-alcoholic steatohepatitisPopulationGastroenterology and HepatologySAF steatosis–activity–fibrosisVALIDATIONER endoplasmic reticulum03 medical and health sciencescDNA complementary DNAInternal medicineALT alanine aminotransferaseGastroenterologiInternal MedicinemedicineNAFL non-alcoholic fatty liverALGORITHMFIB-4 fibrosis-4education030304 developmental biologyPCA principal component analysisScience & TechnologyGastroenterology & HepatologyHepatologybusiness.industryBiomarkerFC fold changemedicine.diseaseBiomarker; MicroRNA; Non-alcoholic fatty liver disease; Sequencingdigestive system diseasesFLIP fatty liver inhibition of progressionCt cycle thresholdSteatosisqPCR quantitative PCRbusinessNon-alcoholic fatty liver disease
researchProduct